Moriwaki Toshikazu

J-GLOBAL         Last updated: Dec 5, 2019 at 02:52
 
Avatar
Name
Moriwaki Toshikazu
E-mail
tmoriwakmd.tsukuba.ac.jp
Affiliation
University of Tsukuba
Section
Faculty of Medicine
Job title
Assistant Professor

Education

 
Apr 1992
 - 
Mar 1998
Kawasaki Medical School
 

Committee Memberships

 
Jun 2013
 - 
Mar 2015
部会員
 

Published Papers

 
Shah, Manish A.;Adenis, Antoine;Enzinger, Peter C.;Kojima, Takashi;Muro, Kei;Bennouna, Jaafar;Francois, Eric;Hsu, Chih-Hung;Moriwaki, Toshikazu;Kim, Sung-Bae;Lee, Se-Hoon;Kato, Ken;Shen, Lin;Qin, Shukui;Ferreira, Paula;Wang, Ruixue;Bhagia, Pooja;Kang, S. Peter;Metges, Jean-Philippe;Doi, Toshihiko
JOURNAL OF CLINICAL ONCOLOGY   37(15::S)    May 2019
Okamoto, Wataru;Nakamura, Yoshiaki;Shiozawa, Manabu;Komatsu, Yoshito;Denda, Tadamichi;Hara, Hiroki;Kagawa, Yoshinori;Narita, Yukiya;Kawakami, Hisato;Esaki, Taito;Nishina, Tomohiro;Izawa, Naoki;Ando, Koji;Moriwaki, Toshikazu;Kato, Takeshi;Nagashima, Fumio;Satoh, Taroh;Nomura, Shogo;Yoshino, Takayuki;Akagi, Kiwamu
JOURNAL OF CLINICAL ONCOLOGY   37(15::S)    May 2019
Masuishi, Toshiki;Moriwaki, Toshikazu;Fukuoka, Shota;Takashima, Atsuo;Kumekawa, Yosuke;Kajiwara, Takeshi;Yamazaki, Kentaro;Esaki, Taito;Makiyama, Akitaka;Denda, Tadamichi;Satake, Hironaga;Suto, Takeshi;Sugimoto, Naotoshi;Katsumata, Kenji;Ishikawa, Toshiaki;Kashiwada, Tomomi;Oki, Eiji;Komatsu, Yoshito;Yoshimura, Kenichi;Shimada, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY   37(15::S)    May 2019
The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
Metges, J.;Francois, E.;Shah, M.;Adenis, A.;Enzinger, P.;Kojima, T.;Muro, K.;Bennouna, J.;Hsu, C.;Moriwaki, T.;Kim, S.;Lee, S.;Kato, K.;Shen, L.;Qin, S.;Ferreira, P.;Wang, R.;Bhagia, P.;Kang, S.;Doi, T.
ANNALS OF ONCOLOGY   30(4)    Jul 2019
Moriwaki, Toshikazu; Sakai, Yoshinori; Ishida, Hiroyasu; Yamamoto, Yoshiyuki; Endo, Shinji; Kuramochi, Hideaki; Sato, Mikio; Hatachi, Yukimasa; Bando, Yoshiaki; Maeba, Takashi; Ikezawa, Kazuto; Shimada, Mitsuo; Amagai, Kenji; Morimoto, Masamitsu; Kobayashi, Kazuma; Tsuji, Akihito; Nishina, Tomohiro; Hyodo, Ichinosuke
International journal of clinical oncology   24(10) 1214-1222   May 2019   [Refereed]
[BACKGROUND] Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic colorectal cancer.
[PATIEN...

Books etc

 
The Practice of Medical Oncology
森脇,俊和 (Part:Contributor, 大腸がん化学療法の三次治療。選ぶのはトリフルリジン/チピラシルか?レゴラフェニブか?)
株式会社ヴァンメディカル   Nov 2019   
Regorafenib treatment for colorectal cancer
森脇,俊和 (Part:Contributor, Evaluating skin disorders and liver injury associated with regorafenib according to the initial dosage)
株式会社アークメディア   Mar 2019   ISBN:9784875832362
Journal of Molecular Targeted Therapy for Cancer
森脇,俊和 (Part:Contributor, What is standard chemotherapy as 2nd- and later-line in patients with advanced gastric cancer?)
メディカルレビュー社   Jul 2018   
消化管Network
山田, 武史;森脇俊和;兵頭一之介 (Part:Contributor, 大腸癌に対する化学療法Up-to-date -分子標的治療薬の位置付けとQOL向上の工夫-)
朝日新聞社   2009   
消化器の臨床
山田, 武史;森脇俊和;兵頭一之介 (Part:Contributor, 消化器癌に対する分子標的治療の今後の展望)
ヴァン・メディカル社   2010   

Conference Activities & Talks

 
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
Shah, Manish A.;Adenis, Antoine;Enzinger, Peter C.;Kojima, Takashi;Muro, Kei;Bennouna, Jaafar;Francois, Eric;Hsu, Chih-Hung;Moriwaki, Toshikazu;Kim, Sung-Bae;Lee, Se-Hoon;Kato, Ken;Shen, Lin;Qin, Shukui;Ferreira, Paula;Wang, Ruixue;Bhagia, Pooja;Kang, S. Peter;Metges, Jean-Philippe;Doi, Toshihiko
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)   31 May 2019   
Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.
Okamoto, Wataru;Nakamura, Yoshiaki;Shiozawa, Manabu;Komatsu, Yoshito;Denda, Tadamichi;Hara, Hiroki;Kagawa, Yoshinori;Narita, Yukiya;Kawakami, Hisato;Esaki, Taito;Nishina, Tomohiro;Izawa, Naoki;Ando, Koji;Moriwaki, Toshikazu;Kato, Takeshi;Nagashima, Fumio;Satoh, Taroh;Nomura, Shogo;Yoshino, Takayuki;Akagi, Kiwamu
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)   31 May 2019   
Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi, Toshiki;Moriwaki, Toshikazu;Fukuoka, Shota;Takashima, Atsuo;Kumekawa, Yosuke;Kajiwara, Takeshi;Yamazaki, Kentaro;Esaki, Taito;Makiyama, Akitaka;Denda, Tadamichi;Satake, Hironaga;Suto, Takeshi;Sugimoto, Naotoshi;Katsumata, Kenji;Ishikawa, Toshiaki;Kashiwada, Tomomi;Oki, Eiji;Komatsu, Yoshito;Yoshimura, Kenichi;Shimada, Yasuhiro
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)   31 May 2019   
Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
森脇, 俊和;長谷川直之;山本祥之;山田武史;金井, 雅史;小林, 省吾;江口, 英利;瀬尾, 智;武冨, 紹信;吉村, 健一;波多野, 悦朗;永野, 浩昭;井岡, 達也
JSCO 57th Annual Meeting 2019   24 Oct 2016   日本癌治療学会
Background: Glasgow prognostic score (GPS), which is defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2), has a prognostic significance in various malignant so...
The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
Metges, J.;Francois, E.;Shah, M.;Adenis, A.;Enzinger, P.;Kojima, T.;Muro, K.;Bennouna, J.;Hsu, C.;Moriwaki, T.;Kim, S.;Lee, S.;Kato, K.;Shen, L.;Qin, S.;Ferreira, P.;Wang, R.;Bhagia, P.;Kang, S.;Doi, T.
European-Society-for-Medical-Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer   3 Jul 2019